[Role of cholecystokinin receptor in methamphetamine-induced reverse tolerance].
Shimazoe
Takao
T
Fukumoto
Takako
T
Shuto
Takahide
T
Watanabe
Shigeki
S
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004361:Drug Tolerance; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage* / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D009473:Neuronal Plasticity / Q000187:drug effects; D010456:Peptides, Cyclic / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*
D001570:Benzodiazepinones; D010456:Peptides, Cyclic; D010671:Phenylurea Compounds; D043886:Receptor, Cholecystokinin A; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; C060101:L 364918; C058121:L 365260; D008694:Methamphetamine; D004298:Dopamine